EU/3/17/1964

Table of contents

About

On 17 January 2018, orphan designation (EU/3/17/1964) was granted by the European Commission to Incyte Biosciences UK Ltd, United Kingdom, for itacitinib for the treatment of graft-versus-host disease.

Key facts

Active substance
Itacitinib
Disease / condition
Treatment of graft-versus-host disease
Date of decision
17/01/2018
Outcome
Positive
Orphan decision number
EU/3/17/1964

Sponsor's contact details

Incyte Biosciences UK Ltd
Riverbridge House
Guildford Road
Leatherhead
Surrey KT22 9AD
United Kingdom
Tel. +44 (0)1372 365900
E-mail: globalmedinfo@incyte.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating